YRRO Ltd agreed to acquire Hemcheck Sweden AB (publ) (OM:HEMC) in a reverse merger transaction for SEK 85.7 million on February 8, 2023. In exchange, Bio Vitos will receive 259,654,000 shares in Hemcheck, amounting to circa 88.3% of Hemcheck's share capital. It is anticipated that subject to all required shareholder and regulatory approvals, that Hemcheck will remain listed on the Nasdaq Stockholm.